Moderna Therapeutics and Novamax Begin Human Trials for COVID-1. Development progress of coronavirus therapy in Wuhan
Let us understand the situation throughly from beginning to end. Patients with new coronavirus infections that originated in
Wuhan, China in December 2019 have been discovered and confirmed in many
countries and regions. The geographic extent of the virus's spread and its
recently discovered ability to spread through human-to-human contact have caused
health officials to worry about the possibility of global spread.
As health officials scramble to learn more about the virus and its origins, researchers are working hard to develop vaccines or therapies that can help curb the global spread of the virus. Experts believe that this is technically feasible, but it also faces challenges.
Dr. Ralph Baric, who studies coronavirus at the School of
Global Public Health at the University of North Carolina at Gillins University,
said that the Wuhan virus (officially named 2019-nCoV) belongs to the
coronavirus family. This category includes SARS (Severe Acute) Respiratory
Syndrome, Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory
Syndrome, Middle East Respiratory Syndrome).
Although the new coronavirus is not exactly the same as SARS, their similarity allows scientists to use previous research experience and results to accelerate the development of vaccines and drugs against Wuhan coronavirus.
Dr. Anthony Fauci, long-time director of the National
Institute of Allergy and Infectious Diseases (NIAID), said that after the SARS
outbreak in 2003, researchers produced a vaccine and pushed it forward.
The first phase of human trials to test the safety of new drugs, but this effort has never made further progress, mainly due to the shift of research focus of participating units as the epidemic ended.
Dr. Fauci said that, theoretically, Chinese researchers have
sequenced the Wuhan coronavirus. It should be fairly easy to adjust the SARS
vaccine model for the unique aspects of Wuhan coronavirus.
Another option is to modify existing monoclonal antibodies that help the immune system attack foreign bodies such as viruses.
"You don't want to be too optimistic, you will indeed encounter obstacles, but fundamentally and conceptually, it is not difficult to achieve this."
Dr. Fauci added that NIAID is working with Moderna, a biotechnology company in Massachusetts, to put an experimental vaccine into a clinical trial.
He estimates that this process will take about three months and
cost millions of dollars.
This does not mean that people can actually be
vaccinated very quickly, because the first phase of the trial is only the first
step towards safe human use, usually after animal studies and before human
studies of drug efficacy.
Whether these projects will proceed further depends largely on the results of the first phase of the trial, the duration and severity of the outbreak. But Dr. Fauci believes that the investment and efforts in this area are totally worthwhile.
Dr. Timothy Sheahan, who studies coronaviruses with Dr. Baric
at the University of North Carolina, said that the development of vaccines may
last longer than the disease. But this does not mean that the development of
the remedy is not worth it.
The Ebola virus is a good example. In 2014, when the Ebola outbreak occurred in West Africa, it was too late when the drugs or vaccines were developed. However, when Ebola virus appeared again in Congo in 2018, the drug / vaccine has been developed. This time, the crisis was promptly responded to and the public health was improved.
Biotech company Moderna is developing vaccines for Wuhan coronavirus
On January 21, 2020, Moderna, a US biotechnology company
founded in 2010, said in a stock exchange report that the company is working
with the US government health agency to develop a vaccine for the current Wuhan
coronavirus.
Specifically, the company is collaborating with the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Vaccine Research Center (VRC) to develop potential vaccines.
Moderna CEO Stephane Bancel revealed that they had produced a cancer vaccine within 40 days.
Tthey are now using the same technology for rapid
development. In a document submitted to the US Securities and Exchange
Commission, the company stated:
"As a fast and flexible platform, Moderna's
mRNA vaccine technology is expected to be useful against emerging virus threats
such as new coronaviruses.
Although we have not tested this before Rapid response capability, but Moderna confirms that it is working with NIH / NIAID / VRC to study potential vaccines for current public health emergencies. "
Development progress of coronavirus therapy in Wuhan
According to Amazon Web Services, Moderna is currently using
Amazon's cloud platform to study more than a dozen drug candidates, seven of
which are in human trials.
Cloud services are used to help accelerate the process from research to clinical trials.
Development progress of coronavirus therapy in Wuhan. Moderna, Novavax of the United States fully develop Wuhan coronavirus vaccine.
(Source: Moderna's official website)
The company stated that they have extensive history and
extensive experience in coronavirus research including MERS and SARS and in the
development of candidate vaccines.
The company said in a statement: "The company hopes to use Novavax's recombinant nanoparticle vaccine technology to develop a candidate vaccine based on the gene sequence of Wuhan coronavirus."
Novavax also plans to make full use of its proprietary Matrix-M adjuvant technology to strive to further enhance the immune response.
The Age of Medicine
In December 2019, patients with new coronavirus infections
who had split their heads in Wuhan, China, have been found and confirmed in
many countries and regions. The geographic reach of the virus and its recently
discovered ability to spread through human-to-human contact have caused health
officials to worry about the possibility of global spread.
As health officials scramble to learn more about the virus and its heads, researchers are working hard to develop vaccines or therapies that can help stop the virus from spreading globally. Experts believe that this is technically feasible, but it also faces provocation.
Dr. Ralph Baric, who studies coronavirus at the School of
Global Public Health at the University of North Carolina at Gillins University,
first described that the Wuhan virus (officially named 2019-nCoV) belongs to
the coronavirus family.
This category includes SARS (Severe Acute Respiratory
Syndrome, severe acute respiratory syndrome) and MERS (Middle East Respiratory
Syndrome, Middle East Respiratory Syndrome).
Although the new coronavirus is not completely similar to SARS, but their similarity can enable scientists to use the previous research history and results to accelerate the development of vaccines and drugs against Wuhan coronavirus.
Dr. Anthony Fauci, who has long served as the director of the
National Institute of Allergy and Infectious Diseases (NIAID), said that after
the outbreak of SARS in 2003, researchers produced a vaccine and pushed it
forward.
To the first phase of human trials to test the safety of new drugs, but this effort never achieved further hope, this is mainly due to the end of the epidemic on-site units shifted the focus of research.
According to Dr. Fauci, in theory, Chinese researchers have
sequenced the Wuhan coronavirus, and it should be fairly easy to mediate the
SARS vaccine model for the unique aspects of Wuhan coronavirus.
Another option is to modify existing monoclonal antibodies that help the immune system attack foreign bodies such as viruses. "You don't want to be overly optimistic, you will indeed encounter obstacles, but fundamentally and conceptually, it is not difficult to do this."
Dr. Fauci added that NIAID is working with Moderna, a
biotechnology company in Massachusetts, to put an experimental vaccine into a
phase 1 clinical trial. He estimates that this process will take about three
months and cost millions of dollars.
This does not mean that people can
actually be vaccinated very quickly, because the first phase of the trial is
only the first step towards safe human use, usually after animal studies and before
human studies of drug efficacy.
Whether these projects are further promoted depends largely on the effectiveness of the first phase of the trial, the duration and severity of the epidemic. But Dr. Fauci believes that the investment and efforts in this area are totally worth it.
Dr. Timothy Sheahan, who studied coronaviruses with Dr. Baric
at the University of North Carolina, showed that the development of vaccines
may last longer than the disease. But this does not mean that it is not worth
opening up.
The Ebola virus is a good example. In 2014, when the Ebola outbreak
occurred in West Africa, it was too late when the drugs or vaccines were
developed.
However, when the Ebola virus appeared again in Congo in 2018, the development of drugs / vaccines was completed. This time, the crisis was promptly addressed and public health improved.
Biotech company Moderna Therapeutics is developing vaccines for Wuhan coronavirus
On January 21, 2020, Moderna, a US biotechnology company
founded in 2010, reflected in a stock exchange report that the company is
cooperating with the U.S. authorities' sanitary gas structure to develop a
vaccine for the current Wuhan coronavirus.
Specifically, the company is working with the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Vaccine Research Center (VRC) to develop potential vaccines.
Stephane Bancel, chief executive officer of Moderna, revealed
that they had produced a cancer vaccine within 40 days; they are now using
similar technologies for rapid development. In a document submitted to the US
Securities and Exchange Commission, the company said:
"As a platform for
rapid mobility, Moderna's mRNA vaccine technology is expected to be effective
against emerging virus threats (such as the new coronavirus).
Moderna confirms that it is working with NIH / NIAID / VRC
Although we have not tested this before Rapid response capability, but Moderna confirms that it is working with NIH / NIAID / VRC to study potential vaccines for current public health emergencies. "
According to Amazon Web Services, Moderna is now using Amazon's cloud platform to study more than a dozen drug candidates, seven of which are in human trials. Cloud services are used to help accelerate the process from research to clinical trials.
In the book of war on January 21, 2020, Novavax (NASDAQ: NVAX) of the United States showed that the company has started to develop candidate vaccines against Wuhan coronavirus.
Novavax's recombinant nanoparticle vaccine technology Use
According to the company, they have extensive history and rich experience in coronavirus research including MERS and SARS and the development of candidate vaccines. The company said in a statement:
"The company hopes to use Novavax's recombinant nano-particle vaccine technology to develop a candidate vaccine based on the gene sequence of Wuhan coronavirus."
Novavax is also planning to make full use of its proprietary Matrix-M adjuvant technology to capture and further enhance the immune response.
Share this in Public Information Interest>>
[[SHARE in Public Health Interest>>
Comments
Post a Comment